Experience with rituximab in refractory idiopathic inflammatory myopathy

Descripción del Articulo

Clinical and laboratory characteristics of two patients who received rituximab for refractory idiopathic inflammatory myopathy (IIM) are described. Patients were refractory to conventional treatment with disease-modifying antirheumatic drugs (DMARDs) so they received rituximab 1 g dose every 14 days...

Descripción completa

Detalles Bibliográficos
Autores: García-Salazar, Elmer R., Becerra, Felipe, Chávez, José
Formato: artículo
Fecha de Publicación:2013
Institución:Universidad Nacional Mayor de San Marcos
Repositorio:Revistas - Universidad Nacional Mayor de San Marcos
Lenguaje:español
OAI Identifier:oai:ojs.csi.unmsm:article/2709
Enlace del recurso:https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/2709
Nivel de acceso:acceso abierto
Materia:Dermatomiositis
miopatía inflamatoria idiopática refractaria
rituximab.
Dermatomyositis
refractory idiopathic inflammatory myopathy
id REVUNMSM_ab17c5f4e07d24deaf2b09ad9ae5701b
oai_identifier_str oai:ojs.csi.unmsm:article/2709
network_acronym_str REVUNMSM
network_name_str Revistas - Universidad Nacional Mayor de San Marcos
repository_id_str
spelling Experience with rituximab in refractory idiopathic inflammatory myopathyExperiencia con rituximab en miopatía inflamatoria idiopática refractariaGarcía-Salazar, Elmer R.Becerra, FelipeChávez, JoséDermatomiositismiopatía inflamatoria idiopática refractariarituximab.Dermatomyositisrefractory idiopathic inflammatory myopathyrituximab.Clinical and laboratory characteristics of two patients who received rituximab for refractory idiopathic inflammatory myopathy (IIM) are described. Patients were refractory to conventional treatment with disease-modifying antirheumatic drugs (DMARDs) so they received rituximab 1 g dose every 14 days in two biannual cycle infusions. Data of proximal muscle strength, pathognomonic skin lesions, CPK, SGOT, LDH and ESR, results of electromyography, muscle and skin biopsy were obtained from the medical records. None of the cases presented drug reaction or infections during and following infusions. Rituximab showed effectiveness in clinical and enzymatic response in patients with dermatomyositis refractory to corticosteroids and traditional DMARDs.Se describe las características clínicas y de laboratorio de dos pacientes que recibieron rituximab por miopatía inflamatoria idiopática(MII). Ellas eran refractarias a tratamiento convencional con DARMES, por lo que recibieron rituximab 1 gramo cada 14 días, en dosinfusiones en ciclo semestral. En las historias clínicas se obtuvo los datos clínicos de fuerza muscular proximal, lesiones cutáneaspatognomónicas, elevación de CPK, TGO, DHL y VSG, resultados de electromiografía, biopsia muscular y de piel. Ninguno de losdos casos presentó reacción medicamentosa ni infecciones durante y posterior a las infusiones. Rituximab mostró efectividad en larespuesta clínica y enzimática en estas pacientes con dermatomiositis refractarias a corticoides y DARMES tradicionales.Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana2013-12-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/270910.15381/anales.v74i4.2709Anales de la Facultad de Medicina; Vol. 74 No. 4 (2013); 331-334Anales de la Facultad de Medicina; Vol. 74 Núm. 4 (2013); 331-3341609-94191025-5583reponame:Revistas - Universidad Nacional Mayor de San Marcosinstname:Universidad Nacional Mayor de San Marcosinstacron:UNMSMspahttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/2709/2362Derechos de autor 2013 Elmer R. García-Salazar, Felipe Becerra, José Chávezhttps://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessoai:ojs.csi.unmsm:article/27092020-04-16T18:16:54Z
dc.title.none.fl_str_mv Experience with rituximab in refractory idiopathic inflammatory myopathy
Experiencia con rituximab en miopatía inflamatoria idiopática refractaria
title Experience with rituximab in refractory idiopathic inflammatory myopathy
spellingShingle Experience with rituximab in refractory idiopathic inflammatory myopathy
García-Salazar, Elmer R.
Dermatomiositis
miopatía inflamatoria idiopática refractaria
rituximab.
Dermatomyositis
refractory idiopathic inflammatory myopathy
rituximab.
title_short Experience with rituximab in refractory idiopathic inflammatory myopathy
title_full Experience with rituximab in refractory idiopathic inflammatory myopathy
title_fullStr Experience with rituximab in refractory idiopathic inflammatory myopathy
title_full_unstemmed Experience with rituximab in refractory idiopathic inflammatory myopathy
title_sort Experience with rituximab in refractory idiopathic inflammatory myopathy
dc.creator.none.fl_str_mv García-Salazar, Elmer R.
Becerra, Felipe
Chávez, José
author García-Salazar, Elmer R.
author_facet García-Salazar, Elmer R.
Becerra, Felipe
Chávez, José
author_role author
author2 Becerra, Felipe
Chávez, José
author2_role author
author
dc.subject.none.fl_str_mv Dermatomiositis
miopatía inflamatoria idiopática refractaria
rituximab.
Dermatomyositis
refractory idiopathic inflammatory myopathy
rituximab.
topic Dermatomiositis
miopatía inflamatoria idiopática refractaria
rituximab.
Dermatomyositis
refractory idiopathic inflammatory myopathy
rituximab.
description Clinical and laboratory characteristics of two patients who received rituximab for refractory idiopathic inflammatory myopathy (IIM) are described. Patients were refractory to conventional treatment with disease-modifying antirheumatic drugs (DMARDs) so they received rituximab 1 g dose every 14 days in two biannual cycle infusions. Data of proximal muscle strength, pathognomonic skin lesions, CPK, SGOT, LDH and ESR, results of electromyography, muscle and skin biopsy were obtained from the medical records. None of the cases presented drug reaction or infections during and following infusions. Rituximab showed effectiveness in clinical and enzymatic response in patients with dermatomyositis refractory to corticosteroids and traditional DMARDs.
publishDate 2013
dc.date.none.fl_str_mv 2013-12-30
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/2709
10.15381/anales.v74i4.2709
url https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/2709
identifier_str_mv 10.15381/anales.v74i4.2709
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/2709/2362
dc.rights.none.fl_str_mv Derechos de autor 2013 Elmer R. García-Salazar, Felipe Becerra, José Chávez
https://creativecommons.org/licenses/by-nc-sa/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2013 Elmer R. García-Salazar, Felipe Becerra, José Chávez
https://creativecommons.org/licenses/by-nc-sa/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
dc.source.none.fl_str_mv Anales de la Facultad de Medicina; Vol. 74 No. 4 (2013); 331-334
Anales de la Facultad de Medicina; Vol. 74 Núm. 4 (2013); 331-334
1609-9419
1025-5583
reponame:Revistas - Universidad Nacional Mayor de San Marcos
instname:Universidad Nacional Mayor de San Marcos
instacron:UNMSM
instname_str Universidad Nacional Mayor de San Marcos
instacron_str UNMSM
institution UNMSM
reponame_str Revistas - Universidad Nacional Mayor de San Marcos
collection Revistas - Universidad Nacional Mayor de San Marcos
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1795238245326389248
score 13.958958
Experience with rituximab in refractory idiopathic inflammatory myopathy
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares